Highly Potent, Water Soluble Benzimidazole Antagonist for Activated α4β1 Integrin
摘要:
The cell surface receptor alpha(4)beta(1), integrin, activated constitutively in lymphoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A). However, concerns on its preliminary pharmacokinetc (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzimidazole moiety, resulting in improved solubility while maintaining picomolar potency [5 (KLCA4); IC50 = 305 pM]. With exceptional solubility, this finding has the potential for improving PK to help diagnose and treat lymphomas.
Highly Potent, Water Soluble Benzimidazole Antagonist for Activated α4β1 Integrin
摘要:
The cell surface receptor alpha(4)beta(1), integrin, activated constitutively in lymphoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A). However, concerns on its preliminary pharmacokinetc (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzimidazole moiety, resulting in improved solubility while maintaining picomolar potency [5 (KLCA4); IC50 = 305 pM]. With exceptional solubility, this finding has the potential for improving PK to help diagnose and treat lymphomas.
Synthesis of Isothiocyanates from Primary Amines via Visible-Light Photocatalysis
作者:Jinglin Ma、Fengxi Li、Chunyu Wang、Zhi Wang、Chuang Du、Lei Wang
DOI:10.1021/acs.orglett.3c02193
日期:2023.8.4
A photocatalyzed, efficient, and mild approach for the synthesis of various substituted isothiocyanates from amine and carbon disulfide was reported in this work. This approach expands the scope of photocatalytic applications and provides a new method for the preparation of aliphatic and aromatic isothiocyanates, which are significant organic building blocks and biological diagnostic markers.
Selectively Targeting T- and B-Cell Lymphomas: A Benzothiazole Antagonist of α<sub>4</sub>β<sub>1</sub> Integrin
作者:Richard D. Carpenter、Mirela Andrei、Olulanu H. Aina、Edmond Y. Lau、Felice C. Lightstone、Ruiwu Liu、Kit S. Lam、Mark J. Kurth
DOI:10.1021/jm800313f
日期:2009.1.8
Current cancer chemotherapeutic agents clinically deployed today are designed to be indiscriminately cytotoxic, however. achieving selective targeting of cancer malignancies would allow for improved diagnostic and chemotherapeutic tools. Integrin alpha(4)beta(1), a heterodimeric cell surface receptor, is believed to have a low-affinity conformation in resting normal lymphocytes and an activated high-affinity conformation in cancerous cells, specifically T- and B-cell lymphomas. This highly attractive yet poorly understood receptor has been selectively targeted with the bisaryl urea peptidomimetic antagonist 1. However. concerns regarding its preliminary pharmacokinetic (PK) profile provided an impetus to change the pharmacophore from a bisaryl urea to a 2-arylaminobenzothiazole moiety, resulting in an analogue with improved physicochemical properties, solubility, and kidney:tumor ratio while maintaining potency (6; IC50 = 53 pM). The results presented herein utilized heterocyclic and solid-phase chemistry, cell adhesion assay, and in vivo optical imaging using the cyanine dye Cy5.5 conjugate.
47. The inhibitory effect of substituents in chemical reactions. Part III. The reactivity of the isothiocyano-group in substituted arylthiocarbimides
作者:Donald W. Browne、G. Malcolm Dyson
DOI:10.1039/jr9340000178
日期:——
Kristian,P. et al., Collection of Czechoslovak Chemical Communications, 1969, vol. 34, p. 563 - 571
作者:Kristian,P. et al.
DOI:——
日期:——
Heterocyclic Ligands for Integrin Imaging and Therapy
申请人:Carpenter Richard D.
公开号:US20100310455A1
公开(公告)日:2010-12-09
The present invention provides α
4
β
1
integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.